Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer.
Carbognin L, Accetta C, Di Giorgio D, Fuso P, Muratore M, Tiberi G, Pavese F, D'Angelo T, Fabi A, Giannarelli D, Di Leone A, Magno S, Garganese G, Sanchez AM, Terribile DA, Franceschini G, Masetti R, Scambia G, Paris I. Carbognin L, et al. Curr Oncol. 2022 Sep 30;29(10):7218-7228. doi: 10.3390/curroncol29100569. Curr Oncol. 2022. PMID: 36290846 Free PMC article.
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.
Bria E, Carbognin L, Furlanetto J, Pilotto S, Bonomi M, Guarneri V, Vicentini C, Brunelli M, Nortilli R, Pellini F, Sperduti I, Giannarelli D, Pollini GP, Conte P, Tortora G. Bria E, et al. Among authors: carbognin l. Cancer Treat Rev. 2014 Aug;40(7):847-56. doi: 10.1016/j.ctrv.2014.05.001. Epub 2014 May 15. Cancer Treat Rev. 2014. PMID: 24877987
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.
Carbognin L, Sperduti I, Nortilli R, Brunelli M, Vicentini C, Pellini F, Pollini GP, Giannarelli D, Tortora G, Bria E. Carbognin L, et al. Cancer Treat Rev. 2015 Mar;41(3):262-70. doi: 10.1016/j.ctrv.2015.02.003. Epub 2015 Feb 9. Cancer Treat Rev. 2015. PMID: 25683304 Review.
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
Carbognin L, Pilotto S, Nortilli R, Brunelli M, Nottegar A, Sperduti I, Giannarelli D, Bria E, Tortora G. Carbognin L, et al. Oncologist. 2016 Mar;21(3):283-91. doi: 10.1634/theoncologist.2015-0307. Epub 2016 Feb 10. Oncologist. 2016. PMID: 26865589 Free PMC article.
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival.
Carbognin L, Sperduti I, Ciccarese M, Fabi A, Petrucelli L, Vari S, Forcignanò RC, Nortilli R, Vicentini C, Pilotto S, Merler S, Zampiva I, Brunelli M, Manfrin E, Giannarelli D, Tortora G, Bria E. Carbognin L, et al. Breast. 2016 Oct;29:24-30. doi: 10.1016/j.breast.2016.06.021. Epub 2016 Jul 7. Breast. 2016. PMID: 27394675
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P. Gamucci T, et al. Among authors: carbognin l. J Cell Physiol. 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. Epub 2017 Sep 27. J Cell Physiol. 2018. PMID: 28710865
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.
Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: carbognin l. Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8. Oncotarget. 2017. PMID: 28969087 Free PMC article.
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.
Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G, Malaguti P, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: carbognin l. Breast. 2018 Oct;41:137-143. doi: 10.1016/j.breast.2018.07.004. Epub 2018 Jul 12. Breast. 2018. PMID: 30092500
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer.
Trestini I, Carbognin L, Monteverdi S, Zanelli S, De Toma A, Bonaiuto C, Nortilli R, Fiorio E, Pilotto S, Di Maio M, Gasbarrini A, Scambia G, Tortora G, Bria E. Trestini I, et al. Among authors: carbognin l. Crit Rev Oncol Hematol. 2018 Sep;129:54-66. doi: 10.1016/j.critrevonc.2018.06.011. Epub 2018 Jun 21. Crit Rev Oncol Hematol. 2018. PMID: 30097238 Free article. Review.
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P. Gamucci T, et al. Among authors: carbognin l. Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7. Cancer Biol Ther. 2019. PMID: 30403909 Free PMC article.
77 results